Natural Capsules Limited
NSE: NATCAPSUQ · Pharmaceuticals · sector
₹140.24NSE close 2026-10-26
Key numbers
Market cap₹146 cr
Price₹140.24
52w high / low₹234 / ₹136
P/E–Sector median 27.9x
P/B0.7xSector median 2.9x
Book value₹212.9
Dividend yield–Sector median 0.48%
ROE-9.5%Sector median 11.7%
ROCE-4.3%Sector median 12.3%
OPM-0.4%Sector median 14.0%
Debt / equity0.52xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-1.1x
Current ratio1.03x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹5 cr vs borrowings ₹114 cr (FY26): borrowings are higher by ₹110 cr.
- Operating profit covered interest -1.1x in the last 12 months.
- Net loss in 5 of the last 6 quarters.
- No dividend in the last 2 financial years.
- Price ₹140.24 on 2026-10-26: -40.1% from the 52-week high, +2.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹324.95 · low ₹140.24
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 45 | 45 | 46 | 38 | 58 | 49 |
| EBITDA | 4 | 0 | -1 | -2 | 1 | 1 |
| OPM % | 9.7% | 0.7% | -1.9% | -6.2% | 2.3% | 2.3% |
| Other income | 0 | 0 | 0 | 0 | 1 | 2 |
| Net profit | 1 | -6 | -7 | -7 | -3 | -4 |
| EPS (₹) | 0.13 | -5.40 | -6.76 | -6.88 | -4.82 | -5.55 |
| Revenue YoY | +30.0% | +7.8% | ||||
| Profit YoY | -763.5% | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 169 | 187 | 191 |
| EBITDA | 18 | -2 | -1 |
| Net profit | 1 | -17 | -22 |
| EPS (₹) | 0.22 | -23.84 | -24.01 |
| Revenue growth | +10.6% | – | |
| Profit growth | -2,853.2% | – | |
| Dividend / share (₹) | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | -32.4% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 233 | 222 |
| Borrowings | 104 | 114 |
| Cash & equivalents | 5 | 5 |
| Total assets | 419 | 424 |
| Fixed assets | 282 | 273 |
| Capital work in progress | 0 | 4 |
| Investments | 3 | 3 |
| Receivables | 62 | 71 |
| Inventory | 25 | 26 |
| Payables | 39 | 55 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 27 | 11 |
| Cash from investing | -44 | -11 |
| Cash from financing | 16 | -1 |
| Capex | 45 | 12 |
| Free cash flow | -18 | -1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 0.3% | -7.7% |
| ROCE % | 2.7% | -5.1% |
| Debtor days | 134 | 139 |
| Inventory days | 109 | 94 |
| Payable days | 166 | 197 |
| Cash conversion cycle (days) | 77 | 36 |
| Working capital days | 64 | 8 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 50.92% |
| FIIs | 0.08% |
| Public (non-institutions) | 49.00% |
| Quarter | Feb 2025 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 51.14% | 51.21% | 51.26% | 51.26% | 51.26% | 51.04% | 50.92% | 50.92% |
| Promoter group | % |
|---|---|
| Tajos Investments Private Limited | 12.04% |
| Nandi Synthetics PVT Ltd | 8.83% |
| Sunil Laxminaryan Mundra | 5.79% |
| Sushil Kumar Mundra | 4.89% |
| Indra Mundra | 3.76% |
| Jyoti Mundra | 2.95% |
| Sharada Mundra | 2.55% |
| Laxminarayan Moondra | 2.31% |
| Radha S Mundra | 2.30% |
| Satyanarayan Mundra | 1.78% |
| Madhav Mundra | 1.59% |
| Shrey Mundra | 1.59% |
| Jyotsna Daga | 0.36% |
| Nidhi Sethia | 0.18% |
| Chandra Rameshwar Laddha | 0.01% |
| Public holders above 1% | % |
|---|---|
| Sangeetha S | 3.14% |
| Anurag Singhi | 1.79% |
| PCG Finvest Private Limited | 1.60% |
| Vivog Commercial Limited | 1.43% |
| Tarinika Management LLP | 1.34% |
| Narendra Dharmsinh Sampat | 1.32% |
| Investor Education and Protection Fund (IEPF) | 1.31% |
8,724 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| NATCAPSUQ | ₹146 cr | – | 0.7x | -9.5% | -4.3% | -0.4% | – | – |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Capsules | ₹174 cr | 92.8% | ₹21 cr | 12.0% |
| API | ₹13 cr | 7.2% | ₹-31 cr | -233.2% |
| Unallocated | ₹0 cr | – | ₹0 cr | – |
| other | ₹0 cr | – | ₹0 cr | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2023-07-20 | Dividend | Final Dividend Rs 1.0 |
| 2022-09-09 | Dividend | Dividend Rs 1.0 |
| 2021-07-06 | Dividend | Final Dividend Rs 1.0 |
| 2020-08-12 | Dividend | Dividend Rs 0.6 |
| 2019-08-13 | Dividend | Final Dividend Rs 1.0 |
Documents
- Annual report FY26
- Annual report FY25
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | NATCAPSUQ |
| BSE code | 524654 |
| ISIN | INE936B01015 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.